Key Points {#FPar1}
==========

Opioids increase the risk of delirium in elderly patients.Although there are some indications that meperidine and tramadol increase the risk of delirium, there are no convincing data that the risk of delirium in elderly patients is different for the various types of opioids.The quality of existing research is limited; further comparative research is needed with accurate documentation of the timing and dose of opioids, valid daily measurements to diagnose delirium, and consideration of potential confounding factors for developing delirium.

Introduction {#Sec1}
============

Delirium is an acute confusional state and a serious neuropsychiatric complication. It occurs specifically among hospitalized vulnerable elderly patients who experience acute stressor factors, including infections, new medications, and/or environmental changes \[[@CR1]\]. Ten to thirty percent of patients admitted to hospital develop delirium \[[@CR2]\]. Delirium is associated with poor functional recovery \[[@CR3]\] and leads to increased morbidity, mortality, and healthcare costs \[[@CR4], [@CR5]\]. Furthermore, this condition can also be very stressful for the patient's relatives.

It has been shown that patients with delirium have on average 5.2 predisposing factors and 3.0 precipitating factors \[[@CR6]\]. A number of studies reveal medication, specifically opioids, as a precipitating factor \[[@CR4], [@CR7], [@CR8]\]. An association was found between opioids and delirium in patients admitted to an intensive care unit \[[@CR4]\] and with the use of opioids in general \[[@CR8]\]. Pain is an important precipitating factor for delirium as well \[[@CR9]\]. As opioids are frequently used for pain control in elderly patients, both over- and under-treatment may initiate delirium.

The etiology of delirium is usually multifactorial and not completely understood. It is assumed that inflammation plays an important role in the pathophysiology of delirium \[[@CR10]\]. Drug-induced delirium is thought to be the result of overactivity of the dopaminergic system and underactivity of the cholinergic system \[[@CR10]\]. In particular, drugs with more anticholinergic properties increase the risk of delirium \[[@CR11]\]. Furthermore, conditions such as renal failure and inflammation may influence the metabolism and clearance of drugs.

The risk of delirium may differ among the various opioids as a result of their specific pharmacokinetic and pharmacodynamic properties. For example, both meperidine and tramadol have metabolites with high anticholinergic properties \[[@CR12]--[@CR14]\], whereas the 3-glucuronide metabolites of both morphine and hydromorphone have been implicated in neuroexcitation \[[@CR15]\].

Delirium risk may thus be influenced by the choice of type of opioid. To establish whether delirium risk differs between the various opioids, we performed a systematic review.

Methods {#Sec2}
=======

We performed a search in MEDLINE by combining search terms from relevant Cochrane reviews on delirium and opioids \[[@CR1], [@CR8], [@CR16], [@CR17]\]. The search was combined with a specific geriatric search filter and covered a period from 1946 to December 2014 \[[@CR18]\]. The search strategy is added as supplemental data. We manually checked the reference lists of obtained systematic reviews for eligible articles. Selection was first performed on the title and abstract (LS) and second on the full text (LS and BvM). Included were studies written in English or Dutch, limited to randomized controlled trials, prospective and retrospective cohort studies, and case-control studies in hospital, long-term, or palliative care, with delirium as the outcome measure. All types of opioids were included. Exclusion criteria were mean age of the study population below 60 years and opioid-dependent populations. Studies in which a morphine equivalent was used to describe the total dose of multiple or unknown types of opioids or in which the effect of opioids combined with other medications was analyzed (acetaminophen excepted) were excluded. The critical appraisal was performed by two authors (LS and VvdZ) independently by using the quality assessment for cohort studies from the Dutch Cochrane Institute \[[@CR19]\]. The final assessment of the quality was reached through discussion. Each study was scored as high, moderate, or low quality. We extracted data on the study population, definition and incidence of delirium, opioid type, route of administration, dose, and timing. The odds ratio (OR), hazard ratio, or relative risk with 95% confidence interval (CI) of each opioid for delirium were collected as the outcome measure. We intended to pool data, depending on the heterogeneity of the studies.

Results {#Sec3}
=======

The primary search resulted in 966 articles; 924 were excluded based on the title and abstract (Fig. [1](#Fig1){ref-type="fig"}). After reading the full text of the remaining 42 articles and checking reference lists from relevant systematic reviews \[[@CR8], [@CR12]\], six studies were included \[[@CR7], [@CR9], [@CR20]--[@CR23]\]. Excluded studies discussed the effects of opioids in general, reported different types of opioids as morphine equivalents, used cognitive decline (without further specification) as the outcome measure, or reported a mean age of the study population below 60 years. The six included studies investigated eight different opioids: morphine, meperidine, fentanyl, tramadol, oxycodone, codeine, hydromorphone, and hydrocodone.Fig. 1Flow chart

No study was rated as high quality, one study as moderate quality \[[@CR9]\], and five studies were rated as low quality \[[@CR7], [@CR20]--[@CR23]\]. Critical information was often missing, for example, dose, route and timing of administration of the opioid, and important confounders or risk factors for delirium were often not taken into account in the study design and analysis (Table [1](#Tab1){ref-type="table"}).Table 1Critical appraisalStudy, year1. Well-defined study groups2. Selection bias adequately excluded3. Exposition well defined and adequate method of examination of the exposition4. Outcome well defined and adequate method of appraisal of the outcome5. Outcome defined blind before knowledge of the exposition6. Follow-up long enough7. Adequate exclusion of selective loss-to-follow-up8. Most important confounders or prognostic factors are known and taken into account in study design and analysisAssessed qualityAdunsky \[[@CR23]\]YesYesNoUnclearUnclearYesUnclearNoLowBrouquet \[[@CR20]\]YesYesYesNoNoUnclearYesNoLowMarcantonio \[[@CR7]\]YesNoNoYesUnclearYesYesNoLowMorrison \[[@CR9]\]YesYesNoYesUnclearNoUnclearYesModerateNandi \[[@CR21]\]YesNoNoNoUnclearYesYesNoLowShiiba \[[@CR22]\]YesUnclearNoUnclearUnclearUnclearUnclearNoLow

Table [2](#Tab2){ref-type="table"} shows the study characteristics of the six included studies \[[@CR7], [@CR9], [@CR20]--[@CR23]\]. We included two retrospective cohort studies \[[@CR22], [@CR23]\], two prospective cohort studies \[[@CR9], [@CR20]\], and two nested case control studies \[[@CR7], [@CR21]\]. Two studies used a matched case-control design. One matched seven preoperative factors: age; poor cognitive function; poor physical function; alcohol abuse; markedly abnormal preoperative sodium, potassium or glucose levels; aortic aneurysm surgery, and non-cardiac thoracic surgery \[[@CR7]\]. One matched age, type of surgery, and year of surgery \[[@CR21]\].Table 2Study characteristicsReferencesStudy designDepartmentSample size (*n*)Delirium cases sample size (*n*)Included patients (*n*)Age, years (mean, SD)OpioidsOpioid use (*n*)Delirium cases \[*n* (%)\]Method for detecting deliriumAdunsky \[[@CR23]\]Retrospective cohortOrthopedic surgery181329282.3 (7.7)Meperidine4419 (43)CAMMorphine4813 (27)Brouquet \[[@CR20]\]Prospective cohortAbdominal surgery1332811881.3 (4.8)Tramadol6022 (37)CAMNo tramadol5838 (66)Marcantonio \[[@CR7]\]Nested case control^a^Mixed surgical13419124573 (8)Meperidine12359 (48)CAMMorphine7452 (70)Fentanyl239 (39)Oxycodone399 (23)Codeine176 (35)No opioid144(29)Morrison \[[@CR9]\]Prospective cohortOrthopedic surgery62087541Unknown, average above 60Meperidine12927 (21)CAMNo meperidine41260 (15)Nandi \[[@CR21]\]Nested case control^b^Orthopedic surgery20,15798463Unknown, average above 60Hydromorphone28958 (20)See textAny other opioid, no hydromorphone17440 (23)Oxycodone112 (18)Any other opioid, no oxycodone45296 (21)Morphine31 (33)Any other opioid, no morphine46097 (21)Hydrocodone-APAP309 (30)Any other opioid, no hydrocodone-APAP43389 (21)Tramadol192 (11)Any other opioid, no tramadol44496 (22)Shiiba \[[@CR22]\]Retrospective cohortOncological surgeryUnknown2413263 (12.6)Fentanyl636 (17)DSM-IVMorphine6918 (26)*APAP* acetaminophen (paracetamol), *CAM* confusion assessment method, *DSM-IV* Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, *SD* standard deviation^a^Matched on: age; poor cognitive function; poor physical function; alcohol abuse; markedly abnormal preoperative sodium, potassium, or glucose levels; aortic aneurysm surgery; non-cardiac thoracic surgery^b^Matched on: age; type of surgery; year of surgery

All studies were performed in surgery departments. Two studies investigated one opioid compared with any other opioid and four studies compared specific opioids. The number of included patients per study ranged from 92 to 541. Five studies included patients with cognitive impairment. Delirium was diagnosed by the confusion assessment method in four studies, and in one study by the *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition criteria. One study used a different delirium measure method: first, all inpatient charts were screened for delirium, confusion, disorientation, altered/change in mental status, metabolic encephalopathy, delusions, hallucinations, or visual-spatial distortions. Then, the patients who were identified through this screening were checked for the presence of delirium by their institution's morbidity and mortality conference records.

Table [3](#Tab3){ref-type="table"} shows a summary of the study results. The route of administration was not reported in two of six studies and the dose of opioid was unknown in four of six studies. Timing and duration of the administration of the opioid differed between the studies and was not fully described in five of six studies.Table 3Study resultsReferencesAgentControl groupAdministrationDoseTiming and durationType of analysisResult OR/HR/RR (95% CI)Adunsky \[[@CR23]\]MeperidineMorphineIntramuscularSingle 62.4 ± 13.2 mgPerioperativeMultivariateOR 2.5 (1.15--4.17)^a^Adunsky \[[@CR23]\]MorphineMeperidineIntramuscular. SublingualSingle 4.4 ± 1.8 mg morphine sulfate. Single 15 mg morphine immediate releasePerioperativeMultivariateOR 1.3 (0.82--5.81)^a^Brouquet \[[@CR20]\]TramadolNo tramadolIntravenousDaily dose of 300 mgFirst 3 days postoperativeMultivariateHR 7.1 (2.2--22.5)^b^Marcantonio \[[@CR7]\]MeperidineNo opioidEpidural or PCAUnclear24 h before delirium developedUnivariateOR 2.7 (1.3--5.5)Marcantonio \[[@CR7]\]MorphineNo opioidEpidural or PCAUnclear24 h before delirium developedUnivariateOR 1.2 (0.6--2.4)Marcantonio \[[@CR7]\]FentanylNo opioidEpidural or PCAUnclear24 h before delirium developedUnivariateOR 1.5 (0.6--4.2)Marcantonio \[[@CR7]\]OxycodoneNo opioidEpidural or PCAUnclear24 h before delirium developedUnivariateOR 0.7 (0.3--1.6)Marcantonio \[[@CR7]\]CodeineNo opioidEpidural or PCAUnclear24 h before delirium developedUnivariateOR 1.1 (0.4--3.6)Morrison \[[@CR9]\]MeperidineNo meperidineUnknownUnclearPostoperative days 1--3/within 24 h of a delirious episodeMultivariateRR 2.4 (1.3--4.5). Cognitively intact patients: RR 2.6 (0.4--15.8)Nandi \[[@CR21]\]HydromorphoneOther opioidUnknownUnclearIntra- and postoperativeMultivariateOR 0.30 (0.14--0.65)^d^Nandi \[[@CR21]\]OxycodoneOther opioidUnknownUnclear. Controlled releaseIntra- and postoperativeMultivariateOR 0.13 (0.01--1.41)^d^Nandi \[[@CR21]\]MorphineOther opioidUnknownUnclear. Sustained releaseIntra- and postoperativeMultivariateOR 2.32 (0.03--1.97)^d^Nandi \[[@CR21]\]Hydrocodone-APAPOther opioidUnknownUnclearIntra- and postoperativeMultivariateOR 1.94 (0.61--6.22)^d^Nandi \[[@CR21]\]TramadolOther opioidUnknownUnclearIntra- and postoperativeMultivariateOR 0.34 (0.04--2.68)^d^Shiiba \[[@CR22]\]FentanylMorphinePCAUnclearPostoperativeMultivariateOR 0.22 (0.07--0.69)^e^*ADL* activities of daily living, *APAP* acetaminophen (paracetamol), *ASA* American Association of Anaesthesiologists Physical Classification System, *CI* confidence interval, *FIM* functional independence measure, *HR* hazard ratio, *MMSE* Mini Mental State Examination, *OR* odds ratio, *PCA* patient-controlled analgesia, *RAND score* score for biomedical factors, *RR* relative risk, *TUG* timed get up and go test^a^Adjusted for: meperidine; morphine; MMSE (\<24:\>24); age (\>80:\<80 years)^b^Adjusted for: ADL score (\>0); MMSE (\<26); preoperative calcium level (\<2.2 mmol/L); perioperative blood transfusion; TUG (\>20 s); ASA status of 3--4; postoperative administration of tramadol^c^Adjusted for: age; sex; residence in a nursing home; cognitive impairment; FIM score 68--88; FIM score 89--91; RAND score 2--3; RAND score 4--15; abnormal blood pressure on admission; abnormal heart rhythm on admission; chest pain on admission; heart failure on admission; medical complication; parenteral morphine sulfate equivalent (10--30 mg and \<10 mg); received meperidine^d^Adjusted for: pre-operative alcohol use; pre-operative depression; sex^e^Adjusted for: age; sex; pain control: fentanyl

Three studies found a significant risk of delirium from the use of meperidine, compared with other opioids (relative risk 2.4, 95% CI 1.3--4.5) \[[@CR9]\], no opioid (OR 2.7, 95% CI 1.3--5.5) \[[@CR7]\], or morphine (OR 2.5, 95% CI 1.15--4.17) \[[@CR23]\]. The other three studies on different opioids showed the following results: increased risk of delirium of tramadol compared with no opioid (hazard ratio 7.1, 95% CI 2.2--22.5) \[[@CR20]\], decreased risk from hydromorphone compared with other opioids (OR 0.30, 95% CI 0.14--0.65) \[[@CR21]\], and decreased risk from fentanyl compared with morphine (OR 0.22, 95% CI 0.07--0.69) \[[@CR22]\]. Additionally, an interaction was found between morphine and oxycodone: morphine combined with oxycodone led to a significant increase in the risk of delirium \[[@CR21]\].

Characteristics of the included studies, including definition of delirium, dose of opioid, and timing of administration, were not comparable and often not available. Because of this clinical heterogeneity and lack of information, a meta-analysis was not performed.

Discussion {#Sec4}
==========

In this systematic review, we aimed to investigate the difference in the risk of delirium from the use of various types of opioids in the elderly population. We found six studies that met our inclusion and exclusion criteria.

There seems to be an increased risk of delirium from the use of meperidine \[[@CR7], [@CR9], [@CR23]\]. This risk is confirmed by a previous systematic review on the role of postoperative analgesia in delirium and cognitive decline that included three overlapping studies \[[@CR12]\]. An increased risk of delirium owing to tramadol use was only shown in one study of low quality \[[@CR20]\]; however, several case reports support this increased risk \[[@CR24]\]. Despite the relative contraindication for tramadol use in older patients, based on this information, tramadol is still frequently prescribed in the Netherlands: there are 385,043 opioid users aged above 65 years, of whom 232,066 use tramadol or a combination of tramadol and paracetamol (60%) \[[@CR25]\].

This review also suggests a protective effect of hydromorphone and fentanyl on delirium.

None of the included studies were randomized clinical trials and none were scored as high quality. Considering the low quality and small study population of the studies that report these effects, all of the above results should be interpreted with caution.

The low quality of five out of the six studies caused several limitations in the interpretation of the results. There was a big difference between sample size and the number of included patients, which led to a high risk of selection bias. The small study samples increase the risk of chance findings, especially in the studies in which several opioids or several medications were studied. Next, the definition of delirium, cognitive impairment, and co-morbidity varied for the different studies, which make comparisons between the studies near impossible. Details about opioid use, including route of administration, dose, and timing were often lacking. It has been shown that these are important details when studying the effect of opioids on delirium and these have to be documented accurately for good comparison between studies \[[@CR26]--[@CR28]\]. In addition, the studies were all observational in nature and several confounding factors were not taken into account, including pain level, cognitive impairment, and co-morbidities of the included patients \[[@CR9], [@CR28], [@CR29]\]. Preoperative resting pain and the increase in pain level on the first day after surgery are both significant risk factors for postoperative delirium \[[@CR28]\]. Neuropathic pain can activate microglia cells and thus lead to an inflammatory state that is associated with delirium \[[@CR30]\]. Consequently, delirium as a result of pain, not as a result of opioid use, might play an important role in the included studies.

A major strength of our study is our comprehensive search, further enhanced by a specific search filter for use in geriatric medicine \[[@CR18]\]. We have limited our inclusion to comparative research. If we had included case reports, we might have found more indications for tramadol or other opioids as precipitating factors for delirium.

Conclusion {#Sec5}
==========

There are no convincing data that the risk of delirium in elderly patients depends on the type of opioid. Studies performed to date were all observational and of low-to-moderate quality. There are some indications that meperidine increases the risk of delirium in elderly patients. Further comparative research is needed with accurate documentation of the timing and dose of opioids, valid daily measurements to diagnose delirium, and consideration of potential confounding factors for developing delirium.
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